Stephen Pakola, M.D., serves as the Executive Vice President and Chief Medical Officer at REGENXBIO Inc., a leading biotechnology company focused on developing innovative gene therapies. Dr. Pakola brings a wealth of experience in the biopharmaceutical industry, having dedicated his career to advancing treatments for various diseases. He joined REGENXBIO in 2015 and has been instrumental in shaping the company's clinical development strategy, overseeing the advancement of its gene therapy pipeline, and guiding the company through several key milestones. Prior to his role at REGENXBIO, Dr. Pakola held several leadership positions in the industry. He served as the Chief Medical Officer at both Amicus Therapeutics and Avanir Pharmaceuticals, where he played a crucial role in the development and commercialization of novel therapies for rare diseases and central nervous system disorders. Dr. Pakola's expertise extends beyond his industry roles, as he has also contributed to the field through his work as an Assistant Clinical Professor of Medicine at the University of California, San Francisco, and as a practicing physician specializing in internal medicine and rheumatology. As the Chief Medical Officer at REGENXBIO, Dr. Pakola leads the clinical development team, focusing on advancing the company's gene therapy programs through clinical trials and towards regulatory approval. His leadership has been pivotal in the progress of REGENXBIO's lead product candidate, RGX-314, for the treatment of wet age-related macular degeneration, as well as other programs targeting rare diseases and neurodegenerative disorders. Dr. Pakola's dedication to improving patient outcomes through innovative gene therapies continues to drive REGENXBIO's mission to transform the lives of patients with serious and life-threatening conditions.